Advancing into the era of CAR T-cell therapies: Tisagenlecleucel in the treatment of B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma
21 May 2021
byProf. Franco Locatelli, Dr. Udo Holtick, Dr. Francesca Lim
Tisagenlecleucel is the first therapy to be approved by the Singapore Health Sciences Authority under the Cell Tissue and Gene Therapy Product Regulations enacted on 1 March 2021. On 4 March 2021, Novartis organized a launch symposium for tisagenlecleucel, a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of paediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukaemia (ALL) and adults with r/r diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The invited speakers were Prof Franco Locatelli from the Sapienza University of Rome, Italy, Dr Udo Holtick from the University Hospital of Cologne, Germany, and Dr Francesca Lim from Singapore General Hospital, Singapore. Prof William Hwang from National Cancer Centre, Singapore, chaired the symposium.
